Abstract 1824P
Background
Patients with advanced prostate cancer are commonly treated with novel hormonal therapy (NHT). However, treatment patterns following NHT remained unclear. This study evaluated treatment patterns among metastatic castration-resistant prostate cancer (mCRPC) patients with prior NHT.
Methods
This study used the Flatiron Health electronic health records data between 1/1/2013-7/31/2022. NHT-experienced mCRPC patients with ≥ 1 line of therapy (LOT) in the mCRPC setting and without chemotherapy in the last 365 days were included. The first LOT in the post-NHT mCRPC setting was defined as index line. Treatment patterns in the post-NHT mCRPC setting were summarized.
Results
A total of 804 patients (median follow-up: 10.6 months) were included. Of these, 239 (30%) patients used enzalutamide as index LOT, 191 (24%) patients used abiraterone, 171 (21%) used docetaxel, and 203 (25%) used other treatment (Table). Patients receiving prior NHT in the non-metastatic castration-resistant or metastatic castration-sensitive settings were more likely to cycle to NHTs than those receiving prior NHT in the mCRPC setting. The median time on treatment for index LOT was 4.1 months. A total of 126 (16%) patients died within 90 days after index LOT while 494 (61%) patients received a 2nd post-NHT LOT. Subsequently, 104 (13%) patients died within 90 days after the 2nd post-NHT LOT while 265 (33%) patients received a 3rd post-NHT LOT. Most patients received chemotherapy while fewer patients received NHTs in the 2nd and 3rd post-NHT LOTs. Commonly observed treatment sequences included index enzalutamide followed by docetaxel (N=62, 8%), index docetaxel followed by other chemotherapy (N=54, 7%), and index abiraterone followed by docetaxel (N=48, 6%).
Table: 1824P
Treatment patterns in the post-NHT mCRPC setting
NHT-experienced patients with mCRPC (N = 804) | |
Index line (the 1 st post-NHT LOT) | 804 (100%) |
Enzalutamide | 239 (30%) |
Abiraterone | 191 (24%) |
Docetaxel | 171 (21%) |
Other NHTs | 29 (4%) |
Radium-223 | 22 (3%) |
Other chemotherapy | 21 (3%) |
Poly adenosine diphosphate ribose polymerase inhibitors (PARPi) | 8 (1%) |
Other | 123 (15%) |
The 2 nd post-NHT LOT | 494 (61%) |
Docetaxel | 145 (18%) |
Other chemotherapy | 90 (11%) |
Enzalutamide | 58 (7%) |
Abiraterone | 39 (5%) |
Radium-223 | 29 (4%) |
Other NHTs | 21 (3%) |
PARPi | 15 (2%) |
Other | 97 (12%) |
The 3 rd post-NHT LOT | 265 (33%) |
Other chemotherapy | 96 (12%) |
Docetaxel | 58 (7%) |
Enzalutamide | 17 (2%) |
Radium-223 | 16 (2%) |
PARPi | 10 (1%) |
Other NHTs | 9 (1%) |
Abiraterone | 7 (1%) |
Other | 52 (6%) |
Conclusions
The real-world treatment patterns in the post-NHT mCRPC setting are heterogeneous, but the majority of patients attempted additional NHT followed by chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was undertaken by Analysis Group Inc. sponsored by Bristol Myers Squibb.
Disclosure
V.K. Narayan: Financial Interests, Institutional, Research Grant: Pfizer, Janssen Oncology, Merck, Regeneron, BMS, TMunity Therapeutics; Financial Interests, Personal, Advisory Board: BMS, Pfizer, Janssen Oncology, Exelixis, Myovant Sciences, Regeneron, Amgen, AstraZeneca. M. Patel, S. Teitsson, L.C. Rosenblatt: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. X. Yin: Financial Interests, Personal, Full or part-time Employment: BMS. K.A. Betts: Financial Interests, Institutional, Funding, Keith A. Betts is an employee of Analysis Group. Other description if needed Analysis Group received consulting fees from BMS to conduct this study: BMS. I. Pivneva: Financial Interests, Institutional, Funding, I. Pivneva is a full-time employee of Analysis Group. Analysis Group received consulting fees from BMS to conduct this study: BMS. S. Gao: Financial Interests, Institutional, Funding, Sophie Gao is a full-time employee of Analysis Group. Analysis Group received consulting fees from BMS to conduct this study: BMS. M. Sundar: Financial Interests, Institutional, Funding, Manasvi Sundar is an employee of Analysis Group. Other description if needed Analysis Group received consulting fees from BMS to conduct this study: BMS.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15